SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Aurobindo Pharma receives final approval for Montelukast Sodium tablets and Chewable tablets

06 Aug 2012 Evaluate

Aurobindo Pharma has received final approvals from the US Food & Drug Administration (USFDA) to manufacture and market Montelukast Sodium tablets 10mg (ANDA 202468) and Montelukast Sodium Chewable tablets 4mg and 5mg (ANDA 202096). The products are ready for a first-day launch.

Montelukast Sodium tablets 10mg and Chewable tablets 4mg and 5mg are the generic equivalent of Merck & Company Inc’s Singulair tablets 10mg and Chewable tablets 4mg and 5mg respectively. Montelukast Sodium is indicated for Prophylaxis and chronic treatment of asthma in adults and pediatric patients 12 months of age and older.

According to IMS, the annual sales of Montelukast Sodium tablets 10mg is approximately $3.5 billion and that of Montelukast Sodium Chewable tablets is $1.1 billion for the twelve months ending March 2012.

The products have been approved out of Unit VII (SEZ) formulations facility in Hyderabad, India. The company now has a total of 157 ANDA approvals (131 final approvals including 1 from Aurolife Pharma LLC and 26 tentative approvals from USFDA.

Aurobindo Pharma has a product presence in key therapeutic segments like SSPs, cephalosporins, antivirals, CNS, cardio-vascular, gastroenterology, etc. The company is the market leader in semi-synthetic penicillin drugs.

Aurobindo Pharma Share Price

1385.65 -0.45 (-0.03%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×